Ironwood Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Ironwood Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Ironwood Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Ironwood Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Ironwood Pharmaceuticals Inc (Ironwood) is a biotechnology company focused on the research, development, and commercialization of innovative gastrointestinal (GI) products and rare diseases. Its major products include LINZESS (linaclotide), a prescription medication for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), and apraglutide, an investigational drug for short bowel syndrome with intestinal failure (SBS-IF). The company also focuses on the development of CNP-104 and IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as IC/BPS and endometriosis. Ironwood partners with other pharmaceutical companies globally to offer its products in North America, Europe, and Asia. It mainly operates in the US and Switzerland. Ironwood is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
100 Summer Street, Suite 2300, Boston, Massachusetts, 02110
Website
www.ironwoodpharma.com
Telephone
1 617 6217722
No of Employees
100
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IRWD (NASD)
Revenue (2024)
$296.2M
-15.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
2629.2%
(2024 vs 2023)
Market Cap*
$693.0M
Net Profit Margin (2024)
XYZ
3,144.0%
(2024 vs 2023)
* As of and is in US$
Ironwood Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Linaclotide: To treat irritable bowel syndrome with constipation, or IBS-C, or chronic idiopathic constipation, or CIC, and for pediatric patients aged 6-17 years old suffering from functional constipation, or FC. | Linzess |
| Pipeline products: | Constella |
| Apraglutide: A potentially differentiated therapy for SBS patients who are dependent on PS. | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In June, the company secured approval from US Food and Drug Administration for LINZESS (linaclotide) to treat pediatric patients ages 6-17 years-old with functional constipation. |
| 2023 | Acquisitions/Mergers/Takeovers | In June, the company acquired VectivBio Holding AG. |
| 2023 | Regulatory Approval | In February, the company announced that the US Food and Drug Administration granted priority review to the supplemental New Drug Application (sNDA) for LINZESS (linaclotide) for the treatment of children and adolescents ages 6-17 years-old with functional constipation. |
Competitor Comparison
| Key Parameters | Ironwood Pharmaceuticals Inc | Takeda Pharmaceutical Co Ltd | Viatris Inc | Bausch Health Companies Inc | Zealand Pharma AS |
|---|---|---|---|---|---|
| Headquarters | United States of America | Japan | United States of America | Canada | Denmark |
| City | Boston | Chuo-Ku | Canonsburg | Laval | Soeborg |
| State/Province | Massachusetts | Tokyo | Pennsylvania | Quebec | - |
| No. of Employees | 100 | 47,455 | 30,000 | 20,300 | 544 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Thomas McCourt | Chief Executive Officer; Director | Executive Board | 2009 | 68 |
| Julie H. McHugh | Chairperson | Executive Board | 2019 | 61 |
| Gregory Martini | Chief Financial Officer; Senior Vice President | Senior Management | 2025 | 38 |
| Jeff Ruberti | Chief Strategy Officer | Senior Management | 2017 | - |
| Michael Shetzline, MD, PhD | Chief Medical Officer; Head - Research and Drug Development; Senior Vice President | Senior Management | 2021 | 67 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer